🇺🇸 SULFADIAZINE, SILVER in United States

67 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Hypersensitivity — 11 reports (16.42%)
  2. Pain — 9 reports (13.43%)
  3. Nausea — 8 reports (11.94%)
  4. Diarrhoea — 7 reports (10.45%)
  5. Drug Ineffective — 6 reports (8.96%)
  6. Skin Ulcer — 6 reports (8.96%)
  7. Abdominal Pain — 5 reports (7.46%)
  8. Anaemia — 5 reports (7.46%)
  9. Asthenia — 5 reports (7.46%)
  10. Condition Aggravated — 5 reports (7.46%)

Source database →

SULFADIAZINE, SILVER in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SULFADIAZINE, SILVER approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for SULFADIAZINE, SILVER in United States?

Marketing authorisation holder not available in our data.